- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06153186
Flunarizine for Treatment Resistant Absence Epilepsy
Study Overview
Status
Intervention / Treatment
Detailed Description
Flunarizine (flunarizine hydrochloride) is indicated for prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded to other treatment and/or in whom other therapy has resulted in unacceptable side effects. Flunarizine readily crosses the blood brain barrier and its primary mechanism of action is to preferentially block the entry of calcium under pathophysiological conditions preventing cellular calcium overload by reducing excessive transmembrane calcium influx.
Flunarizine has been used successfully for many years in children with migraines and is a firstline, though off-label, treatment for alternating hemiplegia of childhood. It is not labeled for the control of seizures, but has been safely trialed as an anti-seizure medication with promising results.
The primary objective is to assess the efficacy, safety and tolerability of flunarizine compared to a baseline period on absence seizures in patients with treatment refractory epilepsy taking a minimum of one anti-seizure medication (ASM). The primary outcome measure is median percent change in weekly absence seizure frequency in patients treated with flunarizine compared with the baseline period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- BC Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is 4 to 18 years of age
- Participant has treatment resistant absence seizures. Treatment resistant absence seizures are defined as failure to respond to 2 or more appropriate anti-seizure medications (ASMs). The potential participant must have failed to respond to or tolerate appropriate doses of two of the following: ethosuximide (>/= 20 mg/kg/day), Valproic acid/divalproex sodium (>/= 15 mg/kg/day) or lamotrigine, (>/= 5 mg/kg/day).
- Participant must currently be taking a minimum of one ASM
- Normal development (may have specific learning disabilities and/or attention deficit hyperactivity disorder/attention deficit disorder (ADHD/ADD))
- EEG confirmation of absence seizures and EEG within 2 months of screening visit
- Absence seizures reported at least 10 times per week
- Participants must have no changes in baseline ASMs for 1 month prior to screening period
- Participant or caregiver can maintain a seizure diary
- Participant is able to swallow capsules
- Written informed consent must be provided. Legal guardians of the participants must be able to understand and provide written consent on behalf of the participant, since study participants may be too young to provide informed consent. For participants 7-18 years of age, assent will be required along with written informed consent of the caregiver.
- The participant is willing and able to attend all study visits at British Columbia (BC) Children's Hospital
- Participant has the ability to speak and read in English
- Females of child bearing potential who are sexually active must be willing to use contraceptive methods for the duration of the study and 6 months post last dose of study drug.
- Males who are sexually active with females of child bearing potential must be willing to use contraception for the duration of the study and 3 months post last dose of study drug.
Exclusion Criteria:
- Age < 4 years, > 18 years
- Participant has uncontrolled myoclonic or generalized tonic clonic seizures
- Psychogenic non-epileptic seizures
- Known diagnosis of intellectual disability
- Autism spectrum disorder
- Participant is taking carbamazepine, oxcarbazepine, phenytoin, eslicarbazepine, or vigabatrin
- History of poor compliance with medication
- Inability of parent or caregiver to maintain a seizure diary
- History of depression or psychosis
- Participant has previously taken flunarizine and has had an adverse reaction to treatment
- Participants who are pregnant or breastfeeding,
- Presence of extrapyramidal symptoms
- Participants who have clinically significant hepatic impairment as assessed by the investigator
- Participants with known hypersensitivity to flunarizine or any of its ingredients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Flunarizine
Flunarizine 5 mg capsules will be administered once a day at night.
If the 5mg/day dose is tolerated by any given participant, the dose will be escalated to 10mg/day taken as two 5mg capsules at night
|
Flunarizine tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Percent Change in Weekly absence seizure frequency
Time Frame: 12 weeks
|
Measuring the median percent change in weekly absence seizure frequency in patients treated with flunarizine compared with the baseline period.
This will be measured by evaluating patient seizure diaries at baseline and at the end of the treatment period
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluating EEG changes in patients with absence epilepsy
Time Frame: 12 weeks
|
Median percent change in the number of absence seizures captured on EEG, and bursts of spike/wave lasting 2 or more seconds in patients treated with flunarizine compared with the baseline period
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy, Generalized
- Epileptic Syndromes
- Epilepsy
- Epilepsies, Myoclonic
- Myoclonic Epilepsy, Juvenile
- Epilepsy, Absence
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Flunarizine
Other Study ID Numbers
- H19-00185
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Myoclonic Epilepsy
-
King's College LondonKing's College Hospital NHS Trust; Charles University, Czech Republic; Hopital... and other collaboratorsRecruitingJuvenile Myoclonic EpilepsyUnited States, Canada, Czechia, Denmark, Estonia, France, Italy, Norway, United Kingdom
-
Lars Bo AndersenUnknownEpilepsy | Seizure Disorder | Epileptic Seizures | EpilepsiaDenmark
-
Universiteit AntwerpenUniversitaire Ziekenhuizen KU Leuven; KU Leuven; University Hospital, Antwerp; Research...CompletedDravet Syndrome | Severe Myoclonic Epilepsy of InfancyBelgium
-
University of TurkuUnknownUnverricht-Lundborg SyndromeFinland
-
National Institute of Neurological Disorders and...Completed
-
Eisai LimitedTerminatedEpilepsyAustralia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
-
Autifony Therapeutics LimitedRecruitingMyoclonus Epilepsies, ProgressiveUnited States
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedChildhood or Juvenile Absence EpilepsyFrance
-
University College, LondonUniversity of North Carolina, Chapel Hill; NYU Grossman School of MedicineRecruitingDentatorubral-Pallidoluysian AtrophyUnited States, United Kingdom
-
Eisai Inc.AvailableEpilepsies, Myoclonic | Drug Resistant Epilepsy
Clinical Trials on Flunarizine Hydrochloride
-
Shanghai University of Traditional Chinese MedicineCompleted
-
The Third Affiliated hospital of Zhejiang Chinese...Recruiting
-
Johnson & Johnson Pharmaceutical Research & Development...Jan-Cil Italy; Jan-Cil Spain; Jan-Cil UK; Jan-Cil SwitzerlandCompletedMigraine | Human Volunteers
-
Taipei Veterans General Hospital, TaiwanMinistry of Science and Technology, R.O.C.CompletedChronic Pain | Fibromyalgia | Chronic MigraineTaiwan
-
All India Institute of Medical Sciences, BhubaneswarCompleted
-
Shalamar Institute of Health SciencesNot yet recruitingMigraine | ProphylaxisPakistan
-
Xijing Hospital of Digestive DiseasesCompleted
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownUremic PruritusChina
-
Taipei Veterans General Hospital, TaiwanRecruiting